Answers are grounded in this paper and cite their sources.
Intranasal liposomes target maternal brain to reduce fetal exposure in pregnancy, indicating a safer treatment approach.
Pregnancy-adapted VPA delivery: systemic dosing increases fetal exposure via placental transfer. Intranasal nano-encapsulated VPA targets the maternal brain, reducing systemic and fetal exposure while preserving seizure control and improving reproductive safety.
No takes yet. Share an insight, caveat, or question.
Corradetti et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: